Solstein Capital’s Quest Diagnostics DGX Stock Holding History

Solstein Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91K	Hold	9	–	–	﹤0.01%	395
2026 Q1	$1.76K	Sell	9 -40	-82%	-$7.77K	﹤0.01%	401
2025 Q4	$8.5K	Hold	49	–	–	﹤0.01%	347
2025 Q3	$9.34K	Sell	49 -66	-57%	-$11.7K	﹤0.01%	338
2025 Q2	$20.7K	Buy	115 +106	+1,178%	+$18.4K	0.01%	280
2025 Q1	$1.52K	Hold	9	–	–	﹤0.01%	305
2024 Q4	$1.36K	Hold	9	–	–	﹤0.01%	304
2024 Q3	$1.4K	Hold	9	–	–	﹤0.01%	304
2024 Q2	$1.23K	Hold	9	–	–	﹤0.01%	306
2024 Q1	$1.2K	Hold	9	–	–	﹤0.01%	303
2023 Q4	$1.24K	Hold	9	–	–	﹤0.01%	301
2023 Q3	$1.1K	Hold	9	–	–	﹤0.01%	305
2023 Q2	$1.26K	Hold	9	–	–	﹤0.01%	300
2023 Q1	$1.27K	Hold	9	–	–	﹤0.01%	268
2022 Q4	$1.41K	Hold	9	–	–	﹤0.01%	278
2022 Q3	$1K	Hold	9	–	–	﹤0.01%	297
2022 Q2	$1K	Hold	9	–	–	﹤0.01%	339
2022 Q1	$1K	Hold	9	–	–	﹤0.01%	372
2021 Q4	$2K	Sell	9 -1,040	-99%	-$158K	﹤0.01%	397
2021 Q3	$152K	Buy	1,049 +1,040	+11,556%	+$152K	0.09%	150
2021 Q2	$1K	Hold	9	–	–	﹤0.01%	430
2021 Q1	$1K	Buy	+9	New	+$1.11K	﹤0.01%	379
2020 Q4	–	Sell	-9	Closed	-$1K	–	121
2020 Q3	$1K	Hold	9	–	–	﹤0.01%	199
2020 Q2	$1K	Hold	9	–	–	﹤0.01%	207
2020 Q1	$1K	Buy	+9	New	+$932	﹤0.01%	245

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Solstein Capital's DGX Position: Q2 2026 in Review

Solstein Capital held its Quest Diagnostics (DGX) position steady in Q2 2026 at 9 shares worth $1.91K. The position accounts for ﹤0.01% of the portfolio, ranked #395.

Solstein Capital first reported a position in DGX in Q1 2020 and has held it in 25 quarters since. The position peaked at $152K in Q3 2021. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Solstein Capital held 9 shares of Quest Diagnostics worth $1.91K as of Q2 2026.
Solstein Capital left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Solstein Capital's portfolio in Q2 2026, its #395 holding.
Solstein Capital first reported a position in Quest Diagnostics in Q1 2020 and has held it in 25 quarters since.
Solstein Capital's Quest Diagnostics position peaked at $152K in Q3 2021.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Solstein Capital's 13F filing for Q2 2026, filed 13 Aug 2026.